ADAM10 as a biomarker for Alzheimer's disease: A systematic review

Autor(es)

de Almeida, Pereira ; Pedroso, R. Valle ; Silva, T. Vicente ; Manzine, P. R. ; Cominetti, M. R.

• Tipo de documento: Artigo Científico
• Fonte: REVUE NEUROLOGIQUE; v. 180, n. 1-2, p. 11-pg., 2024-02-02.

Resumo

Background. - Studies have shown that A Disintegrin and Metalloproteinase 10 (ADAM10) is the main a-secretase in the non-amyloidogenic cleavage of the amyloid precursor protein (APP), avoiding the production of amyloid-b peptide (Ab), one of the pathological hallmarks of Alzheimer's disease (AD). Objective. - To investigate ADAM10 from cerebrospinal fluid (CSF) and plasma/serum as a potential biomarker for AD. Methods. - A systematic review was carried out in the MEDLINE/PubMed, Web of Science, Embase, and Scopus databases using the terms and Boolean operators: "Alzheimer" AND "ADAM10" AND "biomarker". Citation searching was also adopted. The inclusion criteria were original studies of ADAM10 in blood or CSF in patients with AD. The risk of bias was assessed using the Quality Assessment Tool for Observational Cohort and Cross -Sectional Studies. The analysis methods were registered in the PROSPERO database (#CRD42021274239). Results. - Of the 97 records screened, 17 were included. There is strong evidence for lower levels of ADAM10 in platelets of persons with AD compared to cognitively healthy participants. On the other hand, higher levels of ADAM10 were found in plasma. Regarding CSF, controversial results were found with lower and higher levels of ADAM10 in persons with AD compared to healthy older adults. The differences may be due to diverse reasons, including different sample collection and processing and different antibodies, highlighting the importance of standardizing the experiments and choosing the appropriate antibodies for ADAM10 detection. Conclusion. - Evidence shows that ADAM10 levels are altered in platelets, plasma, serum, and CSF of individuals with AD. The alteration was evident in all stages of the disease, and (AU)

• Processo FAPESP: 17/18808-5 - Influência do genótipo da apolipoproteína E (APOE) e de fatores neurotróficos nos potenciais evocados (ERP-P300) de idosos com Doença de Alzheimer e idosos saudáveis
• Beneficiário: Renata Valle Pedroso
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 19/02648-4 - Papel de proteínas da via de sinalização da insulina e sua relação com a secretase ADAM10 na Doença de Alzheimer
• Beneficiário: Márcia Regina Cominetti
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 19/26444-9 - Avaliação da atividade da ADAM10 em diferentes frações celulares
• Beneficiário: Maria Patrícia Oliveira Monteiro e Pereira de Almeida
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 21/01906-0 - Expressão e atividade da ADAM10 e níveis de proteínas da via insulínica em células de neuroblastoma em condições de hiperglicêmica e normoglicêmica
• Beneficiário: Marina Mantellatto Grigoli
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 21/01863-9 - Biologia e função de isoformas da ADAM10 para diagnóstico diferencial da Doença de Alzheimer por sensores eletroquímicos
• Beneficiário: Márcia Regina Cominetti
• Modalidade de apoio: Auxílio à Pesquisa - Temático